Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Control BionicsASX:CBL -4.92% Days Sales Outstanding is 93.44 as of Jun. 2026, which is 10% above its 10-year median of 85.02. The stock has 7 warning signs investors should review. Among 811 Medical Devices & Instruments companies, Control Bionics ranks worse than 50.8% on this metric.
The historical rank and industry rank for Control Bionics's Days Sales Outstanding or its related term are showing as below:
ASX:CBL'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.89 Med: 85.02 Max: 112.34
Current: 66.43
During the past 9 years, Control Bionics's highest Days Sales Outstanding was 112.34. The lowest was 45.89. And the median was 85.02.
ASX:CBL's Days Sales Outstanding is ranked worse than 50.8% of 811
companies
in the Medical Devices & Instruments industry
Industry Median: 65.38
vs ASX:CBL: 66.43
Control Bionics's Days Sales Outstanding
increased
from Jun. 2025 (87.31) to Jun. 2026 (93.44).
Control Bionics (ASX:CBL) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Control Bionics Days Sales Outstanding Related Terms
Control Bionics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Control Bionics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CBL vs ABT, SYK, MDT: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Control Bionics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Control Bionics Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Control Bionics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Control Bionics's Days Sales Outstanding falls into.
Control Bionics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Control Bionics (ASX:CBL) has a Days Sales Outstanding of 93.44 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Control Bionics and its competitors. This is 10% above median its historical median of 85.02. Over the past decade, Control Bionics' Days Sales Outstanding has ranged from 45.89 to 112.34. According to the industry distribution chart, Control Bionics ranks #412 out of 811 companies in the Medical Devices & Instruments industry, placing it in the top 50.8%.
Is Control Bionics' Days Sales Outstanding too high?
Control Bionics' current Days Sales Outstanding of 93.44 is 10% above median its 10-year median of 85.02. Over the past 10 years, this metric has ranged from a low of 45.89 to a high of 112.34. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.38. Control Bionics' value of 93.44 is 42.9% above this industry median. Based on the distribution chart, Control Bionics ranks #412 out of 811 companies in the Medical Devices & Instruments industry, which is below the industry midpoint.
How does Control Bionics' Days Sales Outstanding compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Control Bionics ranks #412 out of 811 companies for Days Sales Outstanding. This places Control Bionics in the lower half of its industry. The industry median Days Sales Outstanding is 65.38. Control Bionics' value of 93.44 is 42.9% above this benchmark. Historically, Control Bionics' own Days Sales Outstanding has ranged from 45.89 to 112.34 over the past decade. While the company's 10-year median is 85.02 vs. the industry median of 65.38, Control Bionics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.38, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Control Bionics's current Days Sales Outstanding of 93.44 is 42.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Control Bionics and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Control Bionics's current Days Sales Outstanding is 93.44, which is 10% above median its own 10-year median of 85.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.06 — trading 190% above its estimated fair value. The current Days Sales Outstanding is 93.44, which is 10% above median its 10-year median of 85.02 and 42.9% above the Medical Devices & Instruments industry median of 65.38. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Days Sales Outstanding is 93.44 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CBL has been successfully added to your 
